Your browser is no longer supported. Please, upgrade your browser.
Settings
VXRT [NASD]
Vaxart, Inc.
Index- P/E- EPS (ttm)-0.46 Insider Own0.60% Shs Outstand115.42M Perf Week0.88%
Market Cap1.00B Forward P/E- EPS next Y-0.65 Insider Trans-35.47% Shs Float114.75M Perf Month-5.97%
Income-46.90M PEG- EPS next Q-0.14 Inst Own38.90% Short Float21.66% Perf Quarter-3.60%
Sales1.70M P/S588.88 EPS this Y57.80% Inst Trans28.65% Short Ratio1.50 Perf Half Y-14.39%
Book/sh1.53 P/B5.25 EPS next Y-1.60% ROA-32.50% Target Price13.40 Perf Year-28.05%
Cash/sh1.37 P/C5.86 EPS next 5Y- ROE-39.80% 52W Range3.50 - 24.90 Perf YTD40.63%
Dividend- P/FCF- EPS past 5Y45.00% ROI-24.60% 52W High-67.75% Beta0.33
Dividend %- Quick Ratio15.10 Sales past 5Y-15.30% Gross Margin- 52W Low129.43% ATR0.61
Employees28 Current Ratio15.10 Sales Q/Q-82.80% Oper. Margin- RSI (14)55.98 Volatility6.72% 8.23%
OptionableYes Debt/Eq0.00 EPS Q/Q-548.60% Profit Margin- Rel Volume0.21 Prev Close8.08
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume16.55M Price8.03
Recom2.00 SMA205.76% SMA508.19% SMA20013.98% Volume4,290,768 Change-0.62%
Jun-29-21Downgrade B. Riley Securities Buy → Neutral $13 → $9
Jun-24-21Initiated Jefferies Buy $13
Jun-11-21Initiated Piper Sandler Overweight $18
Aug-12-20Reiterated H.C. Wainwright Buy $7 → $17
Jul-13-20Initiated B. Riley FBR Buy $22
Jul-26-21 11:19AM  
Jul-19-21 06:21PM  
03:12PM  
Jul-15-21 06:06AM  
Jul-14-21 08:50AM  
Jul-09-21 12:02PM  
Jul-08-21 10:53AM  
Jul-07-21 08:00AM  
Jun-30-21 10:16AM  
Jun-22-21 05:56AM  
Jun-15-21 11:50AM  
09:56AM  
Jun-14-21 07:35AM  
Jun-11-21 12:01PM  
08:25AM  
Jun-10-21 11:59AM  
Jun-08-21 05:51AM  
Jun-07-21 03:13PM  
09:00AM  
May-27-21 08:00AM  
May-17-21 09:53AM  
May-15-21 06:45AM  
May-14-21 01:18PM  
11:38AM  
May-12-21 09:38AM  
06:03AM  
May-09-21 02:14PM  
May-07-21 08:00AM  
06:10AM  
May-06-21 11:37AM  
06:35AM  
06:00AM  
May-04-21 04:07PM  
09:57AM  
08:00AM  
07:01AM  
05:18AM  
May-03-21 05:06PM  
04:51PM  
11:35AM  
09:15AM  
08:00AM  
05:42AM  
Apr-30-21 06:17PM  
Apr-29-21 08:00AM  
Apr-27-21 06:05AM  
Apr-26-21 08:00AM  
Apr-23-21 08:00AM  
Apr-22-21 08:00AM  
06:35AM  
Apr-21-21 05:51AM  
Apr-14-21 06:12AM  
Apr-01-21 07:31AM  
06:09AM  
Mar-25-21 11:46AM  
Mar-21-21 08:00AM  
Mar-16-21 04:12PM  
Mar-13-21 06:00AM  
Mar-11-21 09:05PM  
Mar-10-21 06:33AM  
Mar-06-21 08:00AM  
06:50AM  
06:00AM  
Mar-05-21 10:11AM  
06:00AM  
Mar-04-21 04:01PM  
Mar-02-21 02:30PM  
04:23AM  
Mar-01-21 06:04AM  
Feb-25-21 04:01PM  
Feb-24-21 04:01PM  
07:47AM  
Feb-18-21 05:45PM  
Feb-15-21 06:30AM  
Feb-12-21 10:47AM  
Feb-10-21 08:08AM  
Feb-09-21 07:31AM  
Feb-06-21 06:45AM  
Feb-05-21 02:53PM  
07:03AM  
Feb-04-21 03:26PM  
10:09AM  
05:52AM  
03:13AM  
Feb-03-21 08:29PM  
08:25PM  
04:26PM  
11:28AM  
10:06AM  
08:57AM  
08:30AM  
05:31AM  
Feb-02-21 07:10AM  
Jan-30-21 06:15AM  
Jan-29-21 08:00PM  
Jan-28-21 01:36PM  
09:00AM  
Jan-27-21 04:04PM  
08:30AM  
Jan-26-21 08:30AM  
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Echerd MargaretSVP, Principal Accntng OfficerJul 19Option Exercise1.581,8002,8511,800Jul 21 04:32 PM
Echerd MargaretSVP, Principal Accntng OfficerJul 19Sale8.001,80014,4000Jul 21 04:32 PM
Finney Michael J.DirectorJun 18Option Exercise0.6821,70014,756474,272Jun 21 04:44 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 11Option Exercise1.591,8022,8571,802Jun 14 04:16 PM
Yedid Robert A.DirectorJun 11Option Exercise0.3118,2405,65418,240Jun 14 04:17 PM
Yedid Robert A.DirectorJun 11Sale8.6110,00086,1098,240Jun 14 04:17 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 11Sale8.001,80214,4160Jun 14 04:16 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 09Option Exercise1.9147,55590,88347,555Jun 11 04:17 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 09Sale8.0047,555380,4400Jun 11 04:17 PM
Latour WouterDirectorMay 07Option Exercise1.70100,000170,000100,000May 10 05:05 PM
Latour WouterDirectorMay 07Sale7.13100,000712,7500May 10 05:05 PM
Latour WouterDirectorMay 06Option Exercise1.70100,000170,000100,000May 10 05:05 PM
Latour WouterDirectorMay 06Sale6.54100,000653,8900May 10 05:05 PM
Tucker SeanChief Scientific OfficerMar 16Option Exercise6.491,0066,52948,053Mar 19 05:04 PM
Latour WouterDirectorMar 04Option Exercise0.77150,000115,500150,000Mar 05 04:03 PM
Latour WouterDirectorMar 04Sale6.04150,000906,4500Mar 05 04:03 PM
Latour WouterDirectorNov 23Sale6.32333,3342,108,1380Nov 23 08:18 PM
Tucker SeanChief Scientific OfficerAug 13Option Exercise6.494,02626,12951,679Aug 14 04:21 PM